78
Participants
Start Date
May 1, 2019
Primary Completion Date
January 31, 2026
Study Completion Date
March 31, 2026
Insulin
Standard of care insulin for pump or injection and serves as a control
Semaglutide
Injectable weekly GLP-1RA given as open label experimental drug
Dapagliflozin
Oral daily SGLT2 Inhibitor given as experimental drug
Placebo to Dapagliflozin
Placebo to Dapagliflozin given as a control to the experimental drug
Diabetes and Endocrinology Research Center of WNY, Williamsville
Collaborators (1)
University of Glasgow
OTHER
Juvenile Diabetes Research Foundation
OTHER
State University of New York at Buffalo
OTHER